|
|
 |
|
Viewing report
|
|
|
|
Benefit-Risk Appraisal of Medicines: A Systematic Approach to Decision-Making
John Wiley and Sons Ltd, Aug 2009, Pages: 304
Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available.
The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines.
Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors’ new model and analyses the implications of its implementation.
- Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision making
- Contributes important ideas to the debate on benefit-risk appraisal
- Provides a future framework for benefit-risk appraisal of medicines
Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities,, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Pharma Readiness for Personalized Medicine
Personalized Medicine - Scientific and Commercial Aspects
Market Access Korea - Breaking into the Developed World’s Fastest Growing Pharmaceutical Market
Cancer Risk Assessment: Chemical Carcinogenesis, Hazard Evaluation, and Risk Quantification
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2011 Edition
Impact of Counterfeits on Pharmaceutical Industry - Counterfeiting Poses Threats to Patient Safety and Revenues of Pharmaceutical Companies
Project Management for the Pharmaceutical Industry
Evidence-Based Medicine - Current Use and Future Impact on Global Clinical and Reimbursement Practices
Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies' Adoption of New Sales Models and Technologies
Radio Frequency Identification (RFID) in Pharmaceuticals - Supply Chain Security Concerns Provide Impetus for RFID Adoption
|
|
|
|
